Pulmonary arterial hypertension;Hypertension artérielle pulmonaire idiopathique

Revue du Praticien

Volumn 58, Issue 18, 2008, Pages

  Jaïs, Xavier ^a   Sitbon, Olivier ^a   Savale, Laurent ^a   Montani, David ^a   Humbert, Marc ^a   Simonneau, Gérald ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; BOSENTAN; DIURETIC AGENT; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; VASODILATOR AGENT; WARFARIN;

CONGENITAL HEART DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG PRESSURE; PORTAL HYPERTENSION; PULMONARY HYPERTENSION; REVIEW;

ANTICOAGULANTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; DYSPNEA; ENDOTHELINS; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; PHOSPHODIESTERASE INHIBITORS; PROGNOSIS; PROSTAGLANDINS I; RECEPTORS, ENDOTHELIN; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 57749179294     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30.
2. Humbert M, Trembath RC. Genetics of pulmonary hypertension: from bench to bedside. Eur Respir J 2002;20:741-9.
3. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609-16.
4. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-7.
5. Montani D, Jais X, Sitbon O, Capron F, Simonneau G, Humbert M. Hypertension artérielle pulmonaire. Rev Mal Respir 2005;22:651-66.
6. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:S40-7.
7. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:S14-34.
8. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004;25:2243-78.
9. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
10. Naeije R, Vachiery JL. Medical therapy of pulmonary hypertension. Conventional therapies. Clin Chest Med 2001;22:517-27.
11. Bonnin M, Mercier FJ, Sitbon O, et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology. 2005;102:1133-7;discussion 5A-6A.
12. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984;70:580-7.
13. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11.
14. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
15. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
16. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
17. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28:1195-203.
18. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
19. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
20. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9.
21. Galie N, Rubin LJ, Hoeper MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (early study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100.
22. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-44.
23. Barst RJ, Langleben D, Badesh DB, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56.
24. Galie N, Olschewski H, Oudiz R, et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Circulation 2008;117:3010-19
25. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
26. Rothman A, Sklansky MS, Lucas VW, et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999;84:682-6.
27. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The registry of the International Society for heart and lung transplantation: eighteenth official report-2001. J Heart Lung Transplant 2001;20:805-15.